NO production results in suspension-induced muscle atrophy through dislocation of neuronal NOS

Naoki Suzuki,¹,² Norio Motohashi,¹ Akiyoshi Uezumi,¹ So-ichiro Fukada,¹ Tetsuhiko Yoshimura,³ Yasuto Itoyama,² Masashi Aoki,² Yuko Miyagoe-Suzuki,¹ and Shin’ichi Takeda¹

¹Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.
²Department of Neurology, Tohoku University School of Medicine, Sendai, Japan.
³Project of Biofunctional Reactive Species, Yamagata Promotion Organization of Industrial Technology, Matsuei, Yamagata, Japan.

Forkhead box O (Foxo) transcription factors induce muscle atrophy by upregulating the muscle-specific E3 ubiquitin ligases MuRF-1 and atrogin-1/MAFbx, but other than Akt, the upstream regulators of Foxos during muscle atrophy are largely unknown. To examine the involvement of the dystrophin glycoprotein complex (DGC) in regulation of Foxo activities and muscle atrophy, we analyzed the expression of DGC members during tail suspension, a model of unloading-induced muscle atrophy. Among several DGC members, only neuronal NOS (nNOS) quickly dislocated from the sarcolemma to the cytoplasm during tail suspension. Electron paramagnetic resonance spectrometry revealed production of NO in atrophying muscle. nNOS-null mice showed much milder muscle atrophy after tail suspension than did wild-type mice. Importantly, nuclear accumulation of dephosphorylated Foxo3a was not evident in nNOS-null muscle, and neither MuRF-1 nor atrogin-1/MAFbx were upregulated during tail suspension. Furthermore, an nNOS-specific inhibitor, 7-nitroindazole, significantly prevented suspension-induced muscle atrophy. The NF-κB pathway was activated in both wild-type and nNOS-null muscle during tail suspension. We also show that nNOS was involved in the mechanism of denervation-induced atrophy. We conclude that nNOS/NO mediates muscle atrophy via regulation of Foxo transcription factors and is a new therapeutic target for disuse-induced muscle atrophy.

Introduction

Reduced muscle activity such as bed rest, limb immobilization, denervation, or unloading (e.g., tail suspension or space flight) leads to significant muscle atrophy (1, 2). In these conditions, the atrophying muscles show increased rates of protein degradation mainly through activation of the ubiquitin proteasome system (3, 4), and the muscle-specific E3 ubiquitin ligases muscle-specific RING finger protein 1 (MuRF-1) and atrogin-1/muscle atrophy F-box protein (atrogin-1/MAFbx) are commonly upregulated (3, 4). Recent studies further showed that muscle inactivity results in suppression of the IGF-1/PI3K/Akt pathway (5–8) and activation of transcription factors such as the forkhead box O (Foxo) family and NF-κB (9–11).

Foxo family of forkhead transcription factors regulates a variety of biological process such as metabolism, cell proliferation and death, tumor growth, response to stress, and longevity (12–15). Among several DGC members, only neuronal NOS (nNOS) quickly dislocated from the sarcolemma to the cytoplasm during tail suspension. Electron paramagnetic resonance spectrometry revealed production of NO in atrophying muscle. nNOS-null mice showed much milder muscle atrophy after tail suspension than did wild-type mice. Importantly, nuclear accumulation of dephosphorylated Foxo3a was not evident in nNOS-null muscle, and neither MuRF-1 nor atrogin-1/MAFbx were upregulated during tail suspension. Furthermore, an nNOS-specific inhibitor, 7-nitroindazole, significantly prevented suspension-induced muscle atrophy. The NF-κB pathway was activated in both wild-type and nNOS-null muscle during tail suspension. We also show that nNOS was involved in the mechanism of denervation-induced atrophy. We conclude that nNOS/NO mediates muscle atrophy via regulation of Foxo transcription factors and is a new therapeutic target for disuse-induced muscle atrophy.

Nonstandard abbreviations used: DGC, dystrophin glycoprotein complex; EPR, electron paramagnetic resonance; Foxo, forkhead box O; IKKβ, inhibitor of NF-κB kinase β; l-NAME, N-nitro-l-arginine methylster; MAFbx, muscle atrophy F-box protein; MGD, N-methyl-D-glucamine-dithiocarbamate; mTOR, mammalian target of rapamycin; MuRF-1, muscle-specific RING finger protein 1; 7NI, 7-nitroindazole; nNOS, neuronal NOS.

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J Clin Invest. 117:2468–2476 (2007). doi:10.1172/JCI30654.
inhibitor, 7-nitroindazole (7NI), significantly attenuates suspension-induced muscle atrophy. Furthermore, we show the involvement of nNOS in denervation-induced muscle atrophy process. Thus nNOS and NO are to our knowledge new therapeutic targets for disuse-induced muscle atrophy.

Results
nNOS disappears from the sarcolemma during tail suspension. To elucidate molecular mechanisms of unloading-induced muscle atrophy, we performed tail suspension (14 days) and reloading (7 days) experiments using wild-type C57BL/6 mice. The weights of the soleus and gastrocnemius (Figure 1A) muscles were decreased to 50%–70% of those of the control mice after tail suspension. The mice showed weakened grasping power and less endurance in running on the rotarod test after tail suspension (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI30654DS1). The diameter of myofiber was also drastically decreased (Figure 1B). The expression patterns of the components of DGC, dystrophin, β-dystroglycan, α-sarcoglycan, dystrobrevin, laminin-α2, α1-syntrophin, and caveolin-3 were not changed during tail suspension (data not shown). The serum creatine kinase level was not elevated, and Evans blue dye uptake by myofibers was not evident in atrophied muscles (Supplemental Figure 2), indicating that the sarcolemmal integrity was maintained during tail suspension. nNOS mRNA levels were not significantly reduced (Figure 1F), and total nNOS protein was slightly decreased during tail suspension (Figure 1D). Importantly, immunohistochemistry revealed that nNOS was lost from the sarcolemma during tail suspension (Figure 1C). The sarcolemmal expression was gradually restored during the reloading process.
nNOS-null mice represent tolerance to disuse-induced muscle atrophy. To directly measure the levels of NO in skeletal muscle during tail suspension, we employed electron paramagnetic resonance (EPR) spectrometry with N-nitro-L-arginine methylester (L-NAME; pan-NOS inhibitor) (30) to the wild-type and nNOS-null mice at the final stage of 2-week suspension, sacrificed the mice 30 minutes after the injection, and immediately measured the NO levels in muscle tissues. In EPR, the signal height, which is proportional to the amount of NO, was obtained by measuring the peak-to-peak height of the lower field side signal (arrow in Figure 3A) in the characteristic 3-line NO spectrum (29). NO levels in skeletal muscles increased during tail suspension, and the increase was inhibited by daily administration of 7NI to the mice. We used 50 mg/kg of 7NI to selectively inhibit nNOS (30, 31). The increase of NO levels in skeletal muscle during tail suspension was also inhibited by daily administration of 10 mg/kg of N-nitro-L-arginine methylester (L-NAME; pan-NOS inhibitor) (30) to the same extent (data not shown). NO levels in the skeletal muscle of nNOS-null mice after tail suspension were not different from those of ground control mice (Figure 3B), indicating that nNOS is mainly responsible for elevated levels of NO in muscle during tail suspension. Assay of the catalytic activity of NOS showed a higher level in the soluble (cytoplasmic) fraction than in the particulate fraction of suspended wild-type mice (Figure 3C).

Production of NO by nNOS in tail-suspended skeletal muscle. To directly measure the levels of NO in skeletal muscle during tail suspension, we employed electron paramagnetic resonance (EPR) spectrometry with N-methyl-D-glucamine-dithiocarbamate (MGB) and Fe²⁺ (27, 28). We injected MGD and Fe²⁺ into the wild-type and nNOS-null mice at the final stage of 2-week suspension, sacrificed the mice 30 minutes after the injection, and immediately measured the NO levels in muscle tissues. In EPR, the signal height, which is proportional to the amount of NO, was obtained by measuring the peak-to-peak height of the lower field side signal (arrow in Figure 3A) in the characteristic 3-line NO spectrum (29). NO levels in skeletal muscles increased during tail suspension, and the increase was inhibited by daily administration of 7NI to the

**Figure 2**

nNOS-null mice show partial tolerance to disuse-induced muscle atrophy. (A) Soleus muscle weight from ground control and tail-suspended wild-type (n = 20), nNOS-null (n = 20), eNOS-null (n = 10), and α1-syntrophin–null (n = 10) mice after 2-week tail suspension is shown as percent of wild-type ground controls. **P < 0.01, Student’s t test. (B) Box and whiskers plot of diameter of myofiber in soleus. Diameters were measured on H&E-stained cross sections of soleus muscles. n = 200 fibers in each experiment. *P < 0.05, Student’s t test. (C) Immunoblots of mouse gastrocnemius muscle extracts for DGC components from wild-type ground control (lane 1), wild-type tail-suspended (lane 2), nNOS-null ground control (lane 3), and nNOS-null tail-suspended (lane 4) mice. All lanes contain 30 μg of total protein. The experiments were performed 5 times, and representative pictures are presented.
muscle atrophy (20, 21). EMSA showed that binding activity of NF-κB to its authentic binding sequence is increased by tail suspension in both wild-type and nNOS-null mice (Figure 4D). Importantly, there was no difference between tail-suspended wild-type and nNOS-null mice in the NF-κB binding activity (Figure 4D). In addition, western blotting revealed that p50 is increased by tail suspension (data not shown). These results suggest that NF-κB pathway was activated during tail suspension in the absence of nNOS. Whether the NF-κB activities mediate the residual muscle atrophy that occurred in nNOS-null mice during tail suspension remains to be clarified in a future study.

**Inhibitor of NF-κB kinase B is nitrosylated during tail-suspension**

Foxo3α is known to be phosphorylated by Akt in skeletal muscle (10, 18). In contrast to our expectation, there was no difference between wild-type and nNOS-null mice in the phosphorylation levels of Akt (Figure 5, A and B). There was no difference between the levels of S6k1 and mammalian target of rapamycin (mTOR), which are under regulation by PI3K/Akt signaling and positively regulate protein synthesis between wild-type and nNOS-null mice during tail suspension (5) (Figure 5A). A recent study reported that NO S-nitrosylates inhibitor of NF-κB kinase β (IKKβ) and thereby inhibits its activity (32). Other reports described inhibition of Foxo3α by IKKβ (33). Intriguingly, we found that tyrosine residues of IKKβ were nitrosylated during tail suspension in wild-type mice but not in nNOS-null mice (Figure 5C). However, whether S-nitrosylation of IKKβ detected during tail suspension contributes to activation of Foxo3α remains to be determined.

**7NI alleviates tail suspension–induced muscle atrophy**

To further examine the effect of inhibition of nNOS activity on muscle atrophy, 7NI, a NOS-selective inhibitor, was injected daily into the peritoneal space of the wild-type mice during the 2-week tail suspension (Figure 6). This treatment significantly prevented muscle atrophy during tail suspension but did not increase muscle mass of ground control mice (Figure 6A). 7NI considerably increased phosphorylated Foxo3α and inhibited the increase in dephosphorylated and nuclear Foxo3α during tail suspension (Figure 6C). We also found that upregulation in mRNA levels of MuRF-1 and atrogin-1/MAFbx was abolished by 7NI during tail suspension (Figure 6B). These data imply that nNOS-specific inhibitor is a potential therapeutic strategy for disuse-induced muscle atrophy.

**nNOS-null mice show milder muscle atrophy than wild-type mice after cutting of the sciatic nerve**

We next examined the role of nNOS in denervation-induced muscle atrophy. Cutting the sciatic nerve on the denervated side resulted in greatly reduced muscle weight 14 days after operation (Figure 7A). Importantly, nNOS had already disappeared from the sarcolemma 3 days after denervation (Figure 7A). We observed much milder muscle atrophy in denervated muscle of nNOS-null mice than wild-type mice (Figure 7B), suggesting that nNOS is also involved in denervation-induced muscle atrophy. We then tested whether an nNOS inhibitor (7NI) or a pan-NOS inhibitor (l-NAME) counteracts denervation-induced muscle atrophy (Figure 7B). These 2 inhibitors limited the muscle atrophy (Figure 7B), indicating that NO is indeed a mediator and therefore a therapeutic target for denervation-induced muscle atrophy.

**Discussion**

Dislocation of nNOS is a major step in tail suspension–induced muscle atrophy. Involvement of the DGC in cachexia-induced muscle atrophy was recently reported (22). In our report, we demonstrate for what we believe to be the first time that nNOS is dislocated from the sarcolemma to the cytoplasm during tail suspension, whereas other members of the DGC are normally expressed at the sarcolemma. This observation implies that different mechanisms are involved in unloading-induced muscle atrophy and muscle atrophy seen in cachexia. Sarcolemmal nNOS is reported to be a versatile molecule that modulates satellite cell activation (34), formation of neuromuscular junction (35), glucose uptake (36), muscle contraction, and vasodilation (37). To clarify the mechanisms of nNOS translocation, we examined the effects of clenbuterol, streptomycin, and nifedipine on nNOS dislocation during tail suspension. After administration of these drugs, however, we still observed dislocation of nNOS during tail suspension (data not shown). These results suggest that sympathetic nerves, stretch-activated chan-
Our observations suggest that some posttranslational modifications of nNOS lead to production of NO and regulate Foxo/E3 ubiquitin ligase activity. We clearly show that 2 atrophy-related E3 ubiquitin ligases, MuRF-1 and atrogin-1/MAFbx, are not upregulated in nNOS-null muscle and atrogin-1/MAFbx, are not upregulated in nNOS-null muscle (Figure 2, A and B). iNOS protein was not detected by real-time RT-PCR. *P < 0.05, Mann-Whitney. (B) Representative immunoblot analysis for Foxo3a, phosphorylated Foxo3a (p-Foxo3a), and intranuclear Foxo3a in wild-type and nNOS-null muscle during tail suspension were quantified (n = 5). Note that Foxo3a was dephosphorylated and accumulated in the myonuclei of wild-type mice but not of nNOS-null mice. *P < 0.05, Mann-Whitney. (C) mRNA levels of ubiquitin ligases (MuRF-1 and atrogin-1/MAFbx) (n = 5) were quantified by real-time RT-PCR. *P < 0.05, Mann-Whitney. (D) EMSA of NF-κB binding sites were incubated with nuclear extracts prepared in wild-type and nNOS-null muscle (Figure 6A) but not in 7NI-treated mice (Figure 6A) and in nNOS-null muscle (Figure 6A). Biotin-labeled double-stranded oligonucleotides containing NF-κB binding sites were incubated with nuclear extracts prepared from control and protein-treated muscles. An arrow indicates the DNA-protein complex. LPS was injected intraperitoneally into mice, and the muscle was used as a positive control for NF-κB binding activity. 5x cold, 5-fold excess of nonlabeled competitors.

Figure 4
Participation of nNOS in regulation of Foxo3a and upregulation of MuRF-1 and atrogin-1/MAFbx. (A) The amounts of total Foxo3a, phosphorylated Foxo3a (p-Foxo3a), and intranuclear Foxo3a in wild-type and nNOS-null muscle during tail suspension were quantified (n = 5). Note that Foxo3a was dephosphorylated and accumulated in the myonuclei of wild-type mice but not of nNOS-null mice. *P < 0.05, Mann-Whitney. (B) Representative immunoblot analysis for Foxo3a, phosphorylated Foxo3a, Foxo1, and Foxo4 in total muscle extract, and Foxo3a in nuclear extracts in wild-type ground control (lane 1), wild-type tail-suspended (lane 2), nNOS-null ground control (lane 3), and nNOS-null tail-suspended (lane 4) muscles. α-Tubulin was used as a loading control. (C) Representative immunoblot analysis for MuRF-1 and Atrogin-1 in wild-type and nNOS-null muscle during tail suspension. In contrast, our EMSA showed slight changes in mobility pattern of α-syntrophin during tail suspension (data not shown), suggesting that some posttranslational modifications of α-syntrophin may cause dissociation of nNOS from α-syntrophin.

Dislocated nNOS leads to production of NO and regulates Foxo/E3 ubiquitin ligases pathway. EPR spectrometry confirmed that cytoplasmic nNOS led to production of NO during tail suspension (Figure 3, A and B). Tail suspension-induced muscle atrophy was blunted in nNOS-null mice (Figure 2, A and B) and 7NI-treated mice (Figure 6A) but not in eNOS-null mice (Figure 2, A and B). iNOS protein was not detected by western blotting in skeletal muscle during tail suspension (data not shown). These data indicate that dislocated nNOS, but neither eNOS nor iNOS, is involved in tail suspension–induced muscle atrophy.

We clearly show that 2 atrophy-related E3 ubiquitin ligases, MuRF-1 and atrogin-1/MAFbx, are not upregulated in nNOS-null muscle during tail suspension (Figure 4C and Figure 6B). Therefore, the induction of these genes is a downstream event of dislocation of nNOS in tail suspension–induced muscle atrophy.

Foxo transcription factors are reported to induce skeletal muscle atrophy by upregulating MuRF-1 and atrogin-1/MAFbx (4, 10, 16, 17). For example, transgenic mice overexpressing Foxo1 in skeletal muscle display a decrease in size of muscle fibers (17). Importantly, Foxo3a remained phosphorylated in nNOS-null muscle during tail suspension, and total Foxo3a protein was not increased in tail-suspended nNOS null mice. Moreover, Foxo3a accumulated in the myonuclei of wild-type but not in nNOS-null muscle during tail suspension (Figure 4B and Figure 6C).

When we overexpressed nNOS in muscle cells using a retroviral vector, we found that Foxo3a was activated in nNOS-overexpressing myotubes (Supplemental Figure 4).

How does nNOS/NO regulate Foxo3a pathways? Our observations suggest that nNOS/NO is an upstream regulator of Foxo3a in the tail suspension–induced muscle atrophy process. There are at least 2 possible explanations for how Foxo3a regulates nNOS/NO. First, NO produced by nNOS might inhibit protein kinases, which phosphorylate Foxo3a, thereby protecting Foxo3a from degradation and promoting its translocation from the cytoplasm to the nucleus. There are several kinases that can phosphorylate Foxo, including Akt (10), IKKB (33), BCR (39), and CDK2 (40). In the present study, we show that Akt activities in nNOS-null muscle were not different from those in wild-type muscle during tail suspension. A fraction of IKKB was nitrosylated (inactive) during tail suspension (Figure 5C), but NF-κB was activated in both wild-type and nNOS-null muscle during suspension. This observation suggests that IKKB activity was not meaningfully disrupted (Figure 4D). Involvement of other kinases remains to be investigated in a future study.

Second, nNOS/NO signal might decrease nuclear export of Foxo3a, resulting in accumulation of Foxo3a in myonuclei and protecting it from phosphorylation by Akt. Foxo3a is exported from the nucleus in a 14-3-3 protein–dependent process (19), and these molecular interactions remain to be examined.

Dislocation of nNOS and production of NO have no obvious effects on the activity of NF-κB. It has been reported that reduced muscle activity induces muscle atrophy via activation of both Foxo and NF-κB transcription factors (9), at the same time suppressing the Akt pathway (5, 6), resulting in activation of the transcription of MuRF-1 and atrogin-1/MAFbx genes. In this report we demonstrated that dephosphorylation and nuclear accumulation of Foxo3a were largely attenuated in nNOS-null muscle during tail suspension. In contrast, our EMSA assay suggested that the NF-κB pathway was activated in nNOS-null muscle.
mice to a similar extent as in wild-type mice in tail suspension experiments. This observation raises the possibility that NF-κB-mediated the residual atrophy that occurred in nNOS-null mice, but further investigation is needed to correctly answer this question.

nNOS and other muscle atrophies. Many conditions induce muscle atrophy, including space flight, immobilization, denervation, cancer cachexia, motor neuron diseases, starvation, and aging (41). Recently it has been reported that muscles of tumor-bearing mice exhibited membrane abnormalities accompanied by reduced levels of dystrophin and increased glycosylation on DGC proteins (22, 23). It was also shown that the DGC could counteract atrophic signaling in cancer cachexia when overexpressed at the sarcolemma (22).

In the tail suspension model, we observed dislocation of nNOS but no changes in the sarcolemmal expression of other members of the DGC (Figure 2C). Therefore it is possible that dystrophin deficiency in cancer cachexia induces nNOS dislocation, which results in activation of nNOS and its downstream effectors.

We also found nNOS dislocation in denervation-induced muscle atrophy (Figure 7A). Remarkably, denervation-induced muscle atrophy was modestly blunted in nNOS-null mice or selective nNOS inhibitor–treated mice (Figure 7B). Although iNOS was induced during denervation (data not shown), both 7NI and l-NAME showed a similar effect on muscle atrophy, suggesting that iNOS does not contribute to denervation-induced muscle atrophy.

In conclusion, we demonstrate that nNOS dislocated from the sarcolemma to the cytoplasm in 2 models of disuse-induced muscle atrophy, tail suspension and denervation. We also show that dislocated nNOS led to the production of NO and regulated FoxO3a, MuRF-1, and atrogin-1/MAFbx, key molecules in muscle atrophy. Our model showed a similar effect on muscle atrophy, suggesting that iNOS does not contribute to denervation-induced muscle atrophy.

Methods

Animals and tail suspension model. Twelve-week-old female C57BL/6, nNOS-null and eNOS-null mice were purchased from the Jackson Laboratory. α1-Syntrophin-null mice were produced in our previous study (25). These mice were backcrossed to the C57BL/6 strain for more than 10 generations. The animals were allowed ad libitum access to food and drinking water. The Experimental Animal Care and Use Committee of the National Institute of Neuroscience approved all experimental protocols. The mice were randomly assigned to control or tail suspension groups. To induce muscle atrophy by disuse, mice were suspended so that their hind limbs were 1 mm off the cage floor for 14 days. After 14 days of tail suspension, some groups were allowed 7 days of reloading by normal weight bearing. Muscle weight was normalized to body weight and is presented as a percentage of control in each experiment.

Denervation model. The left sciatic nerve of mice was excised for nearly the full length of the thigh (approximately 10 mm) from a small incision (approximately 4 mm) made in the mid-lateral thigh under general anesthesia under a surgical microscope (Olympus) (42). The mice were sacrificed 3 or 14 days after denervation by cervical dislocation under general anesthesia, and soleus and gastrocnemius muscles were excised for analysis. The right gastrocnemius muscle served as a control.

Reagents. Lipopolysaccharide from E. coli (0.1 ml, 3 mg/kg; E. coli, serotype 055:B5; Sigma-Aldrich) was administered via intraperitoneal injection. 7NI (Dojindo) was dissolved in peanut oil (50 mg/kg). l-NAME was injected daily into the intraperitoneal cavity of mice (10 mg/kg body weight). Clebentol (1 mg/kg; Sigma-Aldrich), streptomycin (300 mg/kg; Sigma-Aldrich) and nifedipine (5 mg/kg; Wako) were dissolved in PBS. PBS was injected into control mice.

Tissue preparation. Control and tail-suspended mice were sacrificed with cervical dislocation. Body and wet muscle were weighed. The gastrocnemius and soleus muscles were collected individually using standard dissection methods and cleaned of excess fat, connective tissue, and tendons. Several of the muscles were frozen in isopentane cooled by liquid nitrogen for histological and immunohistochemical analysis, and the other muscles were frozen directly in liquid nitrogen for RNA isolation or protein extraction and stored at –80 °C.

Real time PCR. Total RNA was isolated using TRIzol (GIBCO). For RT-PCR, first-strand cDNA was synthesized using oligo-dT primers. Expression levels of selected genes (nNOS, MuRF-1, atrogin-1/MAFbx, and 18S-rRNA) were analyzed using Applied Biosystems SYBR Green gene expression assays on ABI7700 Sequence Detection System (Applied Biosystems) following the manufacturer’s instructions.

H&E staining. Ten-micrometer cryosections were cut in the middle part of the muscle belly to obtain the largest myofiber diameter, placed on poly-L-lysine–coated slides, air dried, and stained with H&E. The sections were viewed and photographed using an HC-2500 digital camera (Fuji Photo Film).

Immunohistochemistry. Cryostat sections of muscle tissue (10 μm thick), were postfixed in acetone or 4% paraformaldehyde at –20 °C and preincubated in PBS containing 5% goat serum and 1% bovine serum albumin for 30 minutes at room temperature. Polyclonal anti-nNOS (Zymed), anti-FoxO3a (Sigma-Aldrich), and anti–laminin-α2 (Alexis) were applied overnight at 4 °C. Following incubations with appropriate secondary antibodies, mounted sections were observed by using a Leica confocal microscope. Muscle fiber diameters were determined on cross sections of soleus muscle using the greatest distance between the oppo-
site sides of the narrowest aspect of the fiber. Total number of muscle fibers was also counted on cross sections.

**Western blotting.** Total skeletal muscle protein was extracted from mouse hindlimb muscle for western blot analysis. We used the Bradford method and Coomassie Brilliant Blue G-250 (Bio-Rad) to determine the protein concentrations. Then protein fractions were extracted with a reducing sample buffer containing 10% SDS, 70 mM Tris-HCl, 5% β-mercaptoethanol, and Complete inhibitor cocktail (Roche). Protein (15 or 30 μg per lane) was separated on an SDS-polyacrylamide gel. The resulting gel was subsequently transferred to a polyvinylidene difluoride membrane (Millipore) using 242 mA for 1 hour. The blot was later incubated with primary antibodies. The signals were detected using the enhanced chemiluminescence method (GE Amersham). Relative quantities of proteins in western blots were determined by scanning densitometry (Alpha Innotech) and expressed in arbitrary units. The following antibodies were used for immunoblotting: anti-α1-syntrophin (Biogenesis), anti-laminin-α2 (Alexis), anti-dystrophin (dy2), anti-utrophin, anti-β-dystroglycan, anti-dystrobrevin, anti-dysferlin, anti-caveolin-3 (Novocastra), anti-hsp90 (Stressgen), anti-nNOS, anti-IKKβ, anti-Akt, anti-p-Akt, anti-p-mTOR, anti-p50 (Transduction Laboratories), anti-Foxo3a, anti-p-Foxo3a, anti-Foxo1/4, anti-Na/K-ATPase (Upstate Biotechnology), anti-Hsp70, and anti-iNOS antibody (Santa Cruz Biotechnology Inc.). Anti-α-sarcoglycan antibody was kindly provided by Michihiro Imamura (National Institute of Neuroscience, National Center of Neurology and Psychiatry).

**Figure 6**
7NI alleviates muscle atrophy during tail suspension. (A) Soleus muscle weight of wild-type ground control and wild-type tail-suspended mice with (+7NI) or without 7NI (+oil). Oil or 7NI (50 mg/kg/d) was injected daily into the abdominal cavity of the mice during 2-week tail suspension. Values (muscle weight/body weight) are expressed as percent of wild-type oil-injected muscles after 14-day tail suspension (n = 5–10 per group; *P < 0.05, Mann-Whitney). (B) mRNA levels of MuRF-1 and atrogin-1/MAFbx (n = 4) in muscle from wild-type ground control and wild-type tail-suspended mice with or without 7NI were quantified by real-time RT-PCR (*P < 0.05, Mann-Whitney). (C) The amount of total Foxo3a, dephosphorylated Foxo3a, and intranuclear Foxo3a (n = 4) were analyzed by western blotting, and band densities were normalized to α-tubulin (*P < 0.05, Mann-Whitney).

**Figure 7**
Inhibition of nNOS activities counteracts denervation-induced muscle atrophy. (A) Sarcolemmal expression of nNOS in control and denervated muscles. Transverse muscle sections from denervated (den) and sham-operated mice were stained with anti-nNOS (green) and anti–laminin-α2 chain (red) antibodies 3 days after sciatic nerve excision. Scale bar: 50 μm. (B) Reduction in soleus muscle weight of wild-type and nNOS-null mice 2 weeks after sham operation or denervation. Weight of wild-type denervated muscle was also measured after 2-week administration of oil, 7NI, PBS, or l-NAME. Values (muscle weight/body weight) were expressed as percentage of the values of sham-operated wild-type muscles (n = 5–10 per group). *P < 0.05, Mann-Whitney.
**Nuclear and cytosolic protein extraction.** Nuclear extracts were prepared from mouse skeletal muscle according to the method of Hunter et al. (20). Briefly, the cytosolic extract was obtained from the first supernatant of the nuclear extract preparation. The supernatant was placed in Millipore Ultrafree-4 centrifugal columns that had been pre-wetted with 0.5 ml of dilution buffer (20 mM HEPES, 40 mM KCl, 10% glycerol, 0.2 mM EDTA, 1 mM DTT), and centrifuged (7,500 g) at 4°C for 30 minutes. Dilution buffer (0.8 ml) was added to the column, and the 30-minute spin was repeated. Protein concentrations were determined using the Bradford protein assay (Bio-Rad).

**Immunoprecipitation.** Skeletal muscle samples were homogenized in 0.15 M NaCl, 10 mM HEPES (pH 7.5) and Complete inhibitor cocktail (Roche), with or without 1% digitonin (Wako). nNOS and caveolin-3 immunoprecipitation was performed with anti-nNOS goat polyclonal antibody (Santa Cruz Biotechnology Inc.) and anti–caveolin-3 antibody (Transduction Laboratories). The samples were incubated with protein G gel (GE Amersham) overnight at 4°C. After the gel was washed with the equilibrating buffer, the bound fraction was eluted with 1% SDS, 1 mM tris-(2-carboxyethyl) phosphine, and 0.1 mM EDTA. The samples were then applied to AG50WX-8 columns (Na+ form; Dowex), which were centrifuged, and the supernatant was collected. [3H]-citrulline was quantified by liquid scintillation spectroscopy.

**Subcellular fractionation.** The subcellular fractionation was performed according to the method described by Brenman et al. (24). The gastrocnemius muscle was homogenized in 10 volumes (w/v) of buffer A (25 mM Tris-HCl, pH 7.4, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA). The nuclei of the muscle were pelleted by centrifugation at 1,000 g. The supernatant was then centrifuged at 20,000 g to yield the supernatant S1. The resulting heavy microsomal pellet was resuspended in buffer B (500 mM NaCl added to buffer A), incubated for 30 minutes at 4°C with agitation, and centrifuged at 15,000 g, yielding supernatant S2. The pellet from this last centrifugation was resuspended in buffer B containing 0.5% Triton X-100, incubated for 30 minutes at 4°C with agitation, and centrifuged at 15,000 g to create supernatant S3 and the final pellet. The fractions were resolved using the sample buffer and analyzed by SDS-polyacrylamide gel electrophoresis. The proteins were transferred to a polyvinylidene difluoride membrane (Millipore), which was later incubated with anti-nNOS antibody. The bands were quantified in densitometry.

**Direct measurement of NO by EPR spectrometry.** Concentrations of NO in the skeletal muscle of mice were measured using the NO-trapping technique combined with EPR spectroscopy (29). Spin traps react with unstable free radicals such as NO to form a relatively stable radical adduct. This long-lived adduct formation results in accumulation of a steady-state formation of these free radicals, and thus the resultant radical adduct can be detected readily by EPR spectroscopy. We used a Fe-MGD complex as the trapping agent to quantify NO levels in the skeletal muscle tissues of the mice. Solutions of FeSO₄ (62 mg/kg; Wako) and MGD (348 mg/kg; Dejindo) were injected subcutaneously. The Fe-MGD complex formed had a high specificity for NO (27, 29), and the NO-Fe-MGD complex was detected by EPR spectroscopy. The amplitude of the signal measured from the peak-to-peak height of the lower field side signal in the 3-line spectrum is known to be proportional to the amount of NO (29). The level of NO-Fe-MGD complex was estimated by comparing it with the signal height of a standard solution of a chemically synthesized NO complex. The concentration in tissues was determined 30 minutes after injection of the NO-trapping reagent. Thirty minutes after administration of the reagent, the gastrocnemius and soleus muscle were removed and weighed (approximately 100–120 mg). The tissue was minced and subjected to immediate measurement of NO by EPR spectrometry. X-band EPR spectra were measured at room temperature with a TE-200 EPR spectrometer (JEOL). The homogenates were drawn into a capillary tube (75 mm in length, 46 μl in internal volume) that had been inserted first into an EPR quartz tube (outside diameter, 5 mm), then introduced into the cavity. The instrument settings were as follows: center field, 331 mT; field scan, 4 mT; sweep time, 2 min; time

![Figure 8](https://www.jci.org)  
A model of nNOS involvement in tail suspension–induced muscle atrophy. Under normal conditions nNOS is located at the sarcolemma as a peripheral member of the DGC. During tail suspension, nNOS dissociates from α1-syntrophin (syn) and dislocates into the cytoplasm, generating NO, which ultimately regulates Foxo transcription factors, and muscle-specific E3 ubiquitin ligases, MuRF-1, and atrogin-1/MAFbx, which promote muscle protein degradation by the ubiquitin-proteasome system.
constant, 0.3 s; modulation amplitude, 0.32 mT; modulation frequency, 9.44 GHz; microwave power, 60 mW. Statistical differences were determined by either 2-tailed unpaired Student’s t-test or the Mann-Whitney test. All data are expressed as mean ± SEM. Statistical significance is defined as P < 0.05.

Acknowledgments

We thank S. Masuda, A. Fukase, and T. Harano for technical support; K. Asanuma and J. Yoshitake for EPR spectrometry; Y. Onodera and M. Tateyama for immunohistochemistry; and all members of the Department of Molecular Therapy, National Institute of Neuroscience, for technical assistance and useful discussion, especially M. Yoshida, M. Ikemoto, and Y. Mochizuki. We also thank K. Ono for correcting our English. This work was supported by Research on Nervous and Mental Disorders (grant 16B-2); Health Science Research Grants for research on the human genome and gene therapy (H16-genome-003) and for research on brain science (H15-kokoro-021 and H18-kokoro-019) from the Japanese Ministry of Health, Labor and Welfare; Grants-in-Aid for Scientific Research (14657158, 15390281, 16590333, 17590857, and 18590392) from the Japanese Ministry of Education, Culture, Sports, Science and Technology; and the Ground-based Research Program for Space Utilization, promoted by Japan Space Forum.

Received for publication October 16, 2006, and accepted in revised form May 29, 2007.

Address correspondence to: Shin’ichi Takeda, Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-higashi, Kodaira, Tokyo 187-8502, Japan. Phone: 81-42-346-1720; Fax: 81-42-346-1750; E-mail: takeda@ncnp.go.jp.